乳腺癌的靶向治疗研究进展  

Research Advances in Drug Targets of Breast Cancer

作　　者：许光亚 王婷[1] 李斌[1,2] 时政 XU Guang Ya;WANG Ting;LI Bin;SHI Zheng(School of Basic Medicine,Chengdu University,Chengdu 610106,China;Sichuan Huada Judicial Expertise Institute,Chengdu 610041,China)

机构地区：[1]成都大学基础医学院,成都610106 [2]四川华大司法鉴定所,成都610041

出　　处：《中国药物经济学》2021年第9期125-128,共4页China Journal of Pharmaceutical Economics

基　　金：四川省卫生健康委员会科研课题普及应用项目(19PJ001)。

摘　　要：乳腺癌已经成为全球发病率第一的癌症,严重威胁着人类的生命安全。近年来,分子靶向治疗以特异性高、作用效果好、不良反应小等特点,受到关注,逐渐成为乳腺癌的主流治疗方案。本综述系统回顾了乳腺癌靶向治疗的最新进展,包括靶向哺乳动物雷帕霉素(m TOR)、雌激素受体(ER)、Src酪氨酸激酶、组蛋白去乙酰化酶(HDAC)、聚腺苷二磷酸核糖聚合酶(PARP)、表皮生长因子受体等靶点的抑制剂,从分子靶向治疗的角度为乳腺癌的临床治疗提出新的视角。Breast cancer is the most common cancer in the world,which seriously threatens the safety of human life.In recent years,molecular targeted therapy has attracted close attention due to its high specificity,good effect and small toxic and side effects,and has gradually become the mainstream therapy for breast cancer.This paper systematically reviews the latest advances in targeted therapy for breast cancer,including inhibitors targeting mammaltargets such as rapamycin(mTOR),estrogen receptor(ER),Src tyrosine kinase,histone deacetylase(HDAC),polyadenosine diphosphate ribose polymerase(PARP),epidermal growth factor receptor etc.This paper proposes a new perspective for clinical treatment of breast cancer from the perspective of molecular targeted therapy.

关 键 词：乳腺癌 靶向治疗 药物靶点 研究进展 

分 类 号：R737.9[医药卫生—肿瘤] R979.1[医药卫生—临床医学]